IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer immunotherapy. As the industry prepares for the upcoming patent expiration of Merck's dominant checkpoint inhibitor Keytruda, companies are racing to claim the next oncology backbone. We analyze the three major strategies currently shaping the pipeline: Merck’s platform defense focusing on subcutaneous formulations and early-stage curative intent; the high-risk, high-reward displacement play of PD-1/VEGF bispecific inhibitors spearheaded by players like Akeso and Summit; and AstraZeneca’s tailored, tumor-specific approach combining immunotherapy with antibody-drug conjugates (ADCs) and targeted small molecules. The guests also dissect key clinical insights from the HARMONY-6 Phase 3 trials, the biological and tumor-localization benefits of dual-mechanism molecules over dual-drug cocktails, and the strategic importance of choosing between incremental portfolio expansion and blockbuster-seeking big bets. Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Alex Gray; LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/ Keep up with David Radwaner; LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/ Keep up with Tom Brockbank; LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/   Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA). We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination.   Episode Timestamps 00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic. 00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration. 00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability. 00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation. 00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients. 00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials. 00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence. 00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels.   Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Jason Tardio; LinkedIn: https://www.linkedin.com/in/jason-tardio/   Keep up with Rick Ritacco: LinkedIn: https://www.linkedin.com/in/rritacco/   Follow IDEA Pharma On; Website: https://www.ideapharma.com/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/    

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data.  Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety.  Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems. Don't forget to Like, Share, Subscribe, Rate, and Review!     Keep up with Athina Metaxa; LinkedIn:  https://www.linkedin.com/in/athina-marina-metaxa/     Follow IDEA Pharma On; Website:  https://www.ideapharma.com/     Listen to more fantastic podcast episodes:  https://ideacollider.simplecast.com/

Welcome to IDEA Collider with your host, Rick Ritacco.  In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future.  We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision.  Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites. Don't forget to Like, Share, Subscribe, Rate, and Review!    Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/    Follow IDEA Pharma On; Website: https://www.ideapharma.com/    Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.  The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.